High Prevalence of Chronic GH Deficiency and Approval and Launch of New Products to Augment Growth of Human Growth Hormone Market

Human Growth Hormone Market

 

Human growth hormone is a protein hormone that promotes cellular growth, reproduction, and cell differentiation in humans and many other animals. It is therefore vital in human growth. It helps maintain the normal functioning of the reproductive organs, controls body temperature, orchestrates cell division, orchestrates the development of the nervous system, governs blood pressure, and helps maintain the skin's elasticity. It also has effects on other body tissues such as the eyes, liver, pancreas, kidneys, stomach, and adrenal glands.

Market Dynamics

High prevalence of chronic GH deficiency is expected to boost growth of the global human growth hormone market. For instance, according to the study, “Prevalence of growth hormone deficiency in middle-age adults recovering from stroke”, published in the journal Brain Injury, in October 2019, GHD was diagnosed in 54% of patients, with 32% falling into the severe category.

Moreover, approval and launch of new products is also expected to aid in growth of the market.  For instance, in September 2020, The US Food and Drug Administration approved somapacitan (Sogroya, Novo Nordisk) for the replacement of endogenous growth hormone in adults with growth hormone deficiency.

However, skepticism about over-the-counter human growth hormone claims is expected to hinder growth of the global human growth hormone market. Use of growth hormone therapy in children also increases the risk of cardiovascular diseases in adulthood. Such side effects are also expected to limit the market growth.

Among regions, Asia Pacific is expected to witness significant growth in the global human growth hormone market, owing to approval and launch of new products in the region. For instance, in August 2020, I-Mab, a clinical stage biopharmaceutical company, announced that the China National Medical Products Administration has accepted its pivotal trial application for eftansomatropin (also known as TJ101) as a weekly treatment for growth hormone deficiency in pediatric patients.

Competitive Analysis

Major players operating in the global human growth hormone market include, Pfizer Inc., Genetech Inc., Merck & Co., Eli Lilly And Company, OPKO Health Inc., Novo Nordisk, Sandoz International GmbH, Ferring Holding SA, and Ipsen.

Major players operating in the global human growth hormone market are focused on R&D to expand their product portfolio. For instance, in October 2019, OPKO Health Inc. announced that the global Phase 3 trial evaluating somatrogon dosed once-weekly in pre-pubertal children with growth hormone deficiency (GHD) met its primary endpoint of non-inferiority to daily GENOTROPIN (somatropin) for injection, as measured by annual height velocity at 12 months.

Comments

Popular posts from this blog

Fitness Equipment Market is doing warm-ups to pull growth-rich opportunities from the growing obesity rates accompanied by the sedentary lifestyles

The market for ureteral stents would benefit from the rising prevalence of urological diseases

The North America Vision Care Market Is Driven by the Increasing Prevalence of Eye Diseases in this Region